248 related articles for article (PubMed ID: 20549206)
1. Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners.
Zhu X; Fallert-Junecko BA; Fujita M; Ueda R; Kohanbash G; Kastenhuber ER; McDonald HA; Liu Y; Kalinski P; Reinhart TA; Salazar AM; Okada H
Cancer Immunol Immunother; 2010 Sep; 59(9):1401-9. PubMed ID: 20549206
[TBL] [Abstract][Full Text] [Related]
2. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models.
Zhu X; Nishimura F; Sasaki K; Fujita M; Dusak JE; Eguchi J; Fellows-Mayle W; Storkus WJ; Walker PR; Salazar AM; Okada H
J Transl Med; 2007 Feb; 5():10. PubMed ID: 17295916
[TBL] [Abstract][Full Text] [Related]
3. Brain tumor immunotherapy with type-1 polarizing strategies.
Okada H
Ann N Y Acad Sci; 2009 Sep; 1174():18-23. PubMed ID: 19769732
[TBL] [Abstract][Full Text] [Related]
4. Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10.
Fujita M; Zhu X; Ueda R; Sasaki K; Kohanbash G; Kastenhuber ER; McDonald HA; Gibson GA; Watkins SC; Muthuswamy R; Kalinski P; Okada H
Cancer Res; 2009 Feb; 69(4):1587-95. PubMed ID: 19190335
[TBL] [Abstract][Full Text] [Related]
5. IFN-γ- and IL-17-producing CD8
Ohkuri T; Kosaka A; Ikeura M; Salazar AM; Okada H
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34193567
[TBL] [Abstract][Full Text] [Related]
6. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.
Okada H; Kalinski P; Ueda R; Hoji A; Kohanbash G; Donegan TE; Mintz AH; Engh JA; Bartlett DL; Brown CK; Zeh H; Holtzman MP; Reinhart TA; Whiteside TL; Butterfield LH; Hamilton RL; Potter DM; Pollack IF; Salazar AM; Lieberman FS
J Clin Oncol; 2011 Jan; 29(3):330-6. PubMed ID: 21149657
[TBL] [Abstract][Full Text] [Related]
7. Role of MDA5 and interferon-I in dendritic cells for T cell expansion by anti-tumor peptide vaccines in mice.
Sultan H; Wu J; Kumai T; Salazar AM; Celis E
Cancer Immunol Immunother; 2018 Jul; 67(7):1091-1103. PubMed ID: 29696308
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients.
Migliorini D; Dutoit V; Allard M; Grandjean Hallez N; Marinari E; Widmer V; Philippin G; Corlazzoli F; Gustave R; Kreutzfeldt M; Blazek N; Wasem J; Hottinger A; Koka A; Momjian S; Lobrinus A; Merkler D; Vargas MI; Walker PR; Patrikidou A; Dietrich PY
Neuro Oncol; 2019 Jul; 21(7):923-933. PubMed ID: 30753611
[TBL] [Abstract][Full Text] [Related]
9. Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas.
Pollack IF; Jakacki RI; Butterfield LH; Hamilton RL; Panigrahy A; Normolle DP; Connelly AK; Dibridge S; Mason G; Whiteside TL; Okada H
Neuro Oncol; 2016 Aug; 18(8):1157-68. PubMed ID: 26984745
[TBL] [Abstract][Full Text] [Related]
10. Poly-ICLC preconditioning protects the blood-brain barrier against ischemic injury in vitro through type I interferon signaling.
Gesuete R; Packard AE; Vartanian KB; Conrad VK; Stevens SL; Bahjat FR; Yang T; Stenzel-Poore MP
J Neurochem; 2012 Nov; 123 Suppl 2(Suppl 2):75-85. PubMed ID: 23050645
[TBL] [Abstract][Full Text] [Related]
11. Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial.
Tsuji T; Sabbatini P; Jungbluth AA; Ritter E; Pan L; Ritter G; Ferran L; Spriggs D; Salazar AM; Gnjatic S
Cancer Immunol Res; 2013 Nov; 1(5):340-50. PubMed ID: 24777970
[TBL] [Abstract][Full Text] [Related]
12. Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC.
Okada H; Butterfield LH; Hamilton RL; Hoji A; Sakaki M; Ahn BJ; Kohanbash G; Drappatz J; Engh J; Amankulor N; Lively MO; Chan MD; Salazar AM; Shaw EG; Potter DM; Lieberman FS
Clin Cancer Res; 2015 Jan; 21(2):286-94. PubMed ID: 25424847
[TBL] [Abstract][Full Text] [Related]
13. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines.
Ueda R; Fujita M; Zhu X; Sasaki K; Kastenhuber ER; Kohanbash G; McDonald HA; Harper J; Lonning S; Okada H
Clin Cancer Res; 2009 Nov; 15(21):6551-9. PubMed ID: 19861464
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial.
Kyi C; Roudko V; Sabado R; Saenger Y; Loging W; Mandeli J; Thin TH; Lehrer D; Donovan M; Posner M; Misiukiewicz K; Greenbaum B; Salazar A; Friedlander P; Bhardwaj N
Clin Cancer Res; 2018 Oct; 24(20):4937-4948. PubMed ID: 29950349
[No Abstract] [Full Text] [Related]
15. Cytosolic Receptor Melanoma Differentiation-Associated Protein 5 Mediates Preconditioning-Induced Neuroprotection Against Cerebral Ischemic Injury.
Gesuete R; Christensen SN; Bahjat FR; Packard AE; Stevens SL; Liu M; Salazar AM; Stenzel-Poore MP
Stroke; 2016 Jan; 47(1):262-6. PubMed ID: 26564103
[TBL] [Abstract][Full Text] [Related]
16. Novel antiviral therapeutics to control foot-and-mouth disease.
Dias CC; Moraes MP; Weiss M; Diaz-San Segundo F; Perez-Martin E; Salazar AM; de los Santos T; Grubman MJ
J Interferon Cytokine Res; 2012 Oct; 32(10):462-73. PubMed ID: 22924938
[TBL] [Abstract][Full Text] [Related]
17. Interferon protects mice against inhalation anthrax.
Walberg K; Baron S; Poast J; Schwartz B; Izotova L; Pestka S; Peterson JW
J Interferon Cytokine Res; 2008 Oct; 28(10):597-601. PubMed ID: 18778201
[TBL] [Abstract][Full Text] [Related]
18. Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors.
Hartman LL; Crawford JR; Makale MT; Milburn M; Joshi S; Salazar AM; Hasenauer B; VandenBerg SR; MacDonald TJ; Durden DL
J Pediatr Hematol Oncol; 2014 Aug; 36(6):451-7. PubMed ID: 24309609
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic in situ autovaccination against solid cancers with intratumoral poly-ICLC: case report, hypothesis, and clinical trial.
Salazar AM; Erlich RB; Mark A; Bhardwaj N; Herberman RB
Cancer Immunol Res; 2014 Aug; 2(8):720-4. PubMed ID: 24801836
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Effect of Irreversible Electroporation in Combination with Poly-ICLC Adjuvant in Preclinical Models of Hepatocellular Carcinoma.
Vivas I; Iribarren K; Lozano T; Cano D; Lasarte-Cia A; Chocarro S; Gorraiz M; Sarobe P; Hervás-Stubbs S; Bilbao JI; Casares N; Lasarte JJ
J Vasc Interv Radiol; 2019 Jul; 30(7):1098-1105. PubMed ID: 31101416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
